Canine atopic dermatitis is a chronic, highly pruritic inflammatory skin disease that is commonly seen in dogs. It is believed to be an allergic disease caused by underlying allergic inflammation of the skin due to environmental allergens such as house dust mites, pollen, molds, and other allergens. Canine atopic dermatitis affects dogs worldwide and results in typical lesions of erythema and pruritus that most often involve the face, ear flaps, feet, and folds of the skin. Treatment options include topical therapy with emollients, corticosteroids, antihistamines or calcineurin inhibitors. Oral therapies like cyclosporine, oclacitinib, and aminophylline are also recommended.
The global canine atopic dermatitis treatment drugs market is estimated to be valued at US$ 251.4 million in 2023 and is expected to exhibit a CAGR of 4.1% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
According to the International Veterinary Dermatology Forum, the prevalence of canine atopic dermatitis has increased over the past few years across the globe. Factors such as climate change, indoor living of pets, excessively groomed dogs, early neutering, lack of early microbial exposure, and hereditary factors are responsible for rising prevalence of canine atopy. For instance, according to the Veterinary Information Network (VIN), the prevalence of atopic dermatitis in dogs was reported to be around 10% of insured dogs in the United States in 2016. Also, according to estimates by VIN, the percentage of canine AD increased significantly from 0.5% in 1990 to approximately 10% in 2016 in the U.S. The rising prevalence of canine atopies has led to increasing demand for effective treatment drugs globally. Another driver for the market is flourishing pet care industry worldwide, supported by rising pet ownership, growing humanization of pets, and increasing spending on pet health.
The canine atopic dermatitis treatment drugs market is segmented into systemic drugs and topical drugs. Topical drugs hold the largest market share and are expected to remain the dominating segment over the forecast period. This is because topical drugs are the first line of treatment for atopic dermatitis in dogs, are easily available over the counter, and have fewer side effects compared to systemic drugs. Topical steroids and antihistamines are commonly prescribed as topical drugs.
Political: Regulations regarding the use of corticosteroids and other drugs in animals are becoming stricter. This may limit the use of some existing topical drugs.
Economic: Rising pet ownership and increasing spending on pet care is driving market growth. However, high costs of treatment may restrict the market to some extent.
Social: Growing humanization of pets is leading to rising inclination towards treating pet skin diseases. Also, increasing awareness about atopic dermatitis in dogs is supporting market expansion.
Technological: Advancements in drug delivery systems can help improve the efficacy of treatments and encourage compliance. Online availability of medicines is also improving access and convenience.
The Global Canine Atopic Dermatitis Treatment Drugs Market Size is expected to witness high growth over the forecast period owing to factors such as rising pet adoption, growing expenditure on pet healthcare, and increasing incidence of atopic dermatitis in dogs. The global canine atopic dermatitis treatment drugs market is estimated to be valued at US$ 251.4 million in 2023 and is expected to exhibit a CAGR of 4.1% over the forecast period 2024 to 2031.
Regional analysis: North America holds the largest share of the global market currently due to high pet ownership and expenditure in the region. Asia Pacific is anticipated to be the fastest growing market owing to growing pet care industry and rapidly rising pet population in countries like India and China.
Key players: Key players operating in the canine atopic dermatitis treatment drugs market are Zoetis, Virbac, Elanco Animal Health, Bayer, and Dechra Pharmaceuticals. These companies offer a range of conventional systemic and topical drugs as well as newer targeted therapies for treatment of canine atopic dermatitis.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it